



IROC Rhode Island
640 George Washington Highway
Building B, Suite 201
Lincoln, RI 02865-4207
401-753-7600 (phone) 401-753-7601 (fax)
www.QARC.org

To: ETCTN 10015/SARC-033 Participating Sites
Date: November 13, 2017

Re: 10015: A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma

Please note there has been an unanticipated delay in implementing the TRIAD application for the transfer of imaging for this study. In the meantime it is important that the Diagnostic Studies performed to document patient tumor progression prior to study enrollment and response to treatment are submitted to IROC Rhode Island. Therefore, the diagnostic studies and corresponding radiology reports should be submitted following the alternative methods described below.

Diagnostics Studies in DICOM format can be submitted electronically to IROC Rhode Island via secure FTP (sFTP). Instructions to obtain an sFTP account can be found at <http://irocri.qarc.org>. Click on Digital Data in the top banner from the home page and follow the link labeled DICOM submission via sFTP.

DICOM studies can also be burned to a CD and mailed to IROC Rhode Island at the address above. Multiple studies for the same patient may be submitted on one CD; however, please submit only one patient per CD.

Baseline imaging studies obtained within 30 days prior to day 1 of treatment should be submitted within 4 weeks of enrollment. All follow-up imaging performed after treatment cycles should be submitted within 4 weeks of completion of the scan.

Please contact IROC Rhode Island with any questions regarding this change. IROCRI@QARC.org or 401.753.7600